The Use of Activin/GDF Fusion Protein Is Expected to Treat Pulmonary Hypertension

Pulmonary hypertension (PAH) is an insidious disease. Its symptoms may start slowly, and even before the symptoms appear, extensive damage has caused the blockage of small arteries, resulting in increased blood pressure in the lungs. When the symptoms—the most obvious being shortness of breath—are severe enough for PAH patients to seek treatment and obtain a definite diagnosis, based on currently available treatments, the patient’s chance of survival within five years…

Read More >>